Indian Pediatrics 2006;43:639-642
Methylprednisolone Therapy in a Child with Unresolving ARDS
From the Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India.
Correspondence to: Dr. Rakesh Lodha, Assistant Professor, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India. E-mail: email@example.com
Manuscript received: July 26, 2005; Initial review
completed: October 18, 2005;
Acute Respiratory Distress Syndrome (ARDS) causes significant morbidity and mortality in children in intensive care units throughout the world(1). Irrespective of the underlying initiating cause of ARDS, there is loss of integrity of endothelial cells and damage to Type II pneumocytes which sets into motion an inflammatory cascade that result in extensive damage to lung parenchyma. The initial exudative phase is followed by proliferative phase, which leads to organization of exudates, proliferation of type II pneumocytes, and finally the fibrotic phase occurs by day 10(2). At this stage, steroids may help to check the unabated inflammation in lung tissue and have been used in adults with unresolving ARDS once infection is controlled, with good results(3). There is very limited data regarding its use in children with unresolving ARDS(4,5). We report a case of unresolving ARDS in a 21-month-old child who showed marked improvement with methylprednisolone therapy.
A 21-month-old severely malnourished child weighing 7 kg was admitted with chronic diarrhea. Intestinal biopsy showed eosino-philic gastroenteritis and he failed to gain weight on nutritional management of chronic diarrhea(6), so total parenteral nutrition (TPN) was started. About 4 weeks after starting TPN, he had sudden onset of respiratory distress, which was preceded by an accidental bolus of 5 mL of intralipid infusion via his subclavian venous catheter. The patient had increasing respiratory distress requiring intubation and mechanical ventilation. His tachycardia responded to fluid boluses, and his colour and saturation improved after intubation, Peripheral pulses were of good volume and there were no skin petechiae and no electrolyte abnormalities or hypocalcemia. The child had no bleeding manifestations or thrombocytopenia throughout the course. The possibility of fat embolism was considered initially but no supportive evidence for the same was found subsequently.
The chest X-ray at the time of admission to the Pediatric Intensive Care Unit (PICU) showed bilateral diffuse infiltrates. The central venous pressure (CVP) was 7 cm H2O and an echocardiography ruled out any underlying cardiac dysfunction. The PaO2/FiO2 ratio was 120, the initial PaCO2 was 57.2 mm Hg. The child was ventilated using Siemens Servo 300 ventilator using pressure regulated volume control (PRVC) mode. The initial ventilator settings were: tidal volume 60 mL, PEEP 10 cm H2O, frequency of 30/min and FiO2 of 100% and 1:E = 1:2 (Ti = 0.7 second). A diagnosis of ARDS was considered. The child received intravenous (IV) antibiotics (Vancomycin, Pipercillin + Tazobactam and Amikacin) and antifungals (Amphotericin B, started prior to this event in view of urinary Candida infection initially). Serial arterial blood gases were done to optimize ventilatory management.
The patient continued to require high settings (PEEP 12 cm H2O, FiO2 >60%) without any improvement in clinical condition and the chest X-ray showed progressive worsening with a complete whiteout. Cultures (bacterial and fungal) from blood, urine and non-bronchoscopic bronchoalveolar lavage (BAL) fluid, which were done twice weekly, were repeatedly sterile. Cytopathology of BAL fluid showed some neutrophils. After 10 days of positive pressure ventilation and progressively worsening lung picture with no evidence of infection, a possibility of unresolving ARDS was considered and and a decision to administer methylprednisolone was taken, as per the protocol given by Meduri, et al.(3): Loading dose of 2 mg/kg, then 2 mg/kg/day from day 1-14; 1 mg/kg/day from day 15-21: 0.5 mg/kg/day from day 22-28; 0.25 mg/kg/day on days 29 and 30 and finally 0.125 mg/kg on days 31 and 32. The PaO2/FiO2 ratio at this time was 120 and the PEEP was 12 cm H2O. Written informed consent from the parents was obtained prior to initiating therapy.
The patient showed improvement, thereafter, in chest findings along with recuction in PEEP to 5 cm H2O by day 4 of starting methylprednisolone and gradual decrease in FiO2 requirements. PaO2/FiO2 ratio improved to 314 by day 4 and by day 8, the child was stable at PEEP of 5 cm H2O and FiO2 of 30%. The chest X-ray also showed clearing of the diffuse infiltrates and the patient was finally extubated after 10 days of methyl-prednisolone therapy. The child maintained normal saturations on oxygen by head box and was then gradually weaned off oxygen and shifted to the inpatient ward, where he received further treatment. No infectious complications, hyperglycemia, hypertension or muscle weakness occurred in the child.
The Institute Ethics Committee waived off the need for informed consent for reporting this case.
We successfully used steroid therapy in a young child with unresolving ARDS. We could wean off ventilation a patient who was not responding to all supportive care including high ventilatory support over 10 days. There are trials of methylprednisolone in unresolving ARDS in adults but pediatric data is limited to case reports(4,5).
In unresolving ARDS, the failure to suppress the sustained systemic inflammatory response could be due to inadequacy of and/ or tissue resistance to the endogenous glucocorticoids. Of the two cellular signaling pathways -the stimulatory nuclear factor kB (NF-kB) and the inhibitory Glucocorticoid Receptor-a (GR-a) mediated responses - there is increase in GR-a and suppression of NF-kB mediated responses with use of steroids. In addition, levels of cytokines, ACTH and cortisol showed significant reductions(7) and the serial measurement of plasma and BAL Procollagen Type I and III amino terminal propeptides (which reflect collagen synthesis)(8) suggests that steroid therapy reduces fibrogenesis and the chronic lung changes in unresolving ARDS.
Meduri, et al. reported use of steroid therapy in adults with unresolving ARDS who failed to show improvement in lung injury scores (LIS) by day 7(3), with improvement in lung function and mortality as primary outcomes and improvement in MODS score and rate of development of nosocomial infections as the secondary outcomes. The study showed reduced LIS, improved PaO2/FIO2, decreased MODS score, and successful extubation in treatment group and rate of infections/day of treatment was similar, with pneumonia being frequently detected in the absence of fever by regular bronchoscopy and assessment of BAL fluid.
There is limited pediatric data, In a case series, the authors used initial short course high dose therapy (30 mg/kg) for 3-6 days, starting from day 4-31 after onset of ARDS in 6 children(4). There is also a single case report from Malaysia in which methylprednisolone therapy was used in a child with unresolving ARDS after 12 days of mechanical ventilation(5).
The following pre-conditions should be met before starting steroids in a patient with unresolving ARDS(3): (i) The patient must have no demonstrable infection; (ii) Steroids should not be started <7 days or >28 days, from admission; (iii) There should be no history of gastric ulceration or active gastrointestinal bleeding; (iv) Patients with burns requiring skin grafting, AIDS, and those in whom life support is expected to be withdrawn, are unsuitable; (v) The patient should have evidence of ALI and require FiO2 >50%; (vi) Screening for LRTI, by performing protected lavage every 3 to 4 days (while the patient is ventilated), and line sepsis.
To conclude, steroid therapy may have a role in the treatment of unresolving ARDS, provided infection is well controlled. The review of the available literature regarding its use in children highlights the limited experience. Further studies are required to define the optimal time of starting therapy, its duration and doses in children with unresolving ARDS.
Contributors: LG, SJ, RL were involved in the management of the case and writing of the report. RL will act as the guarantor.
Competing interests: None.